Twelve AITL cases were identified carrying three mutations (TET2, IDH2R172, DNMT3A) and the seven cases with available overall‐survival data showed significantly inferior clinical outcome (Figure 1E). Here, TET2 is linked to angioimmunoblastic T-cell lymphoma.